<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03935074</url>
  </required_header>
  <id_info>
    <org_study_id>10136532</org_study_id>
    <nct_id>NCT03935074</nct_id>
  </id_info>
  <brief_title>Superselective Intra-arterial Chemotherapy Treatment for Retinoblastoma- 5 Year Results From Turkey</brief_title>
  <official_title>Superselective Intra-arterial Chemotherapy Treatment for Retinoblastoma- 5 Year Results From Turkey</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istanbul University-Cerrahpasa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istanbul University-Cerrahpasa</source>
  <brief_summary>
    <textblock>
      Retrospective review of 5-year long term outcomes of superselective intra-arterial
      chemotherapy treatment in retinoblastoma in a single institute.

      The treatment outcomes, globe salvage rates and complications of superselective
      intra-arterial chemotherapy both for treating naive patients (primary treatment group) and
      for patients who received systemic chemotherapy previously (secondary treatment group) were
      evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 30, 2016</start_date>
  <completion_date type="Actual">November 30, 2016</completion_date>
  <primary_completion_date type="Actual">November 30, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>globe salvage</measure>
    <time_frame>2-5 years</time_frame>
    <description>globe salvage rate after superselective intra-arterial chemotherapy treatment for retinoblastoma</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">30</enrollment>
  <condition>Retinoblastoma</condition>
  <arm_group>
    <arm_group_label>group 1</arm_group_label>
    <description>Patients who received intra-arterial chemotherapy as a first line treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 2</arm_group_label>
    <description>Patients who received intra-arterial chemotherapy as a salvage treatment after systemic chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intra-arterial administration of melphalan</intervention_name>
    <arm_group_label>group 1</arm_group_label>
    <arm_group_label>group 2</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with retinoblastoma and who received superselective intra-arterial
        chemotherapy as a first line treatment or as a salvage treatment after systemic
        chemotherapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients diagnosed with unilateral/bilateral retinoblastoma

        Exclusion Criteria:

          -  patients with trilateral retinoblastoma

          -  extraoculer involvement

          -  patients with blood dyscrasias, bleeding and clotting disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Months</minimum_age>
    <maximum_age>7 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Istanbul University Cerrahpasa School of Medicine Ophthalmology Department</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Saglam M, Sarici A, Anagnostakou V, Yildiz B, Kocer N, Islak C, Kizilkilic O. An alternative technique of the superselective catheterization of the ophthalmic artery for intra-arterial chemotherapy of the retinoblastoma: retrograde approach through the posterior communicating artery to the ophthalmic artery. Neuroradiology. 2014 Sep;56(9):751-4. doi: 10.1007/s00234-014-1388-1. Epub 2014 Jun 10.</citation>
    <PMID>24913287</PMID>
  </reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 30, 2019</study_first_submitted>
  <study_first_submitted_qc>April 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2019</study_first_posted>
  <last_update_submitted>May 2, 2019</last_update_submitted>
  <last_update_submitted_qc>May 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istanbul University-Cerrahpasa</investigator_affiliation>
    <investigator_full_name>Bilge Batu Oto</investigator_full_name>
    <investigator_title>Ophthalmology Specialist, Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>enucleation</keyword>
  <keyword>globe salvage</keyword>
  <keyword>superselective intra-arterial chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinoblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

